
Cupid, Ather Energy, and Laurus Labs are among the top six stocks which have quietly rallied up to the tune of 200% in the last six months despite market volatility. Here's what investors need to know.
as of 21/11/2026, 7:02:28 pm
02/Price history
5 years · weekly candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.
| 16 Nov 2026 | 2,430.00 | 2,439.00 | 2,190.00 | 2,294.60 | -5.57% | 249.00 | 1.61 Cr |
| 9 Nov 2026 | 2,351.50 | 2,488.00 | 2,351.50 | 2,424.00 | +3.08% | 136.50 | 1.22 Cr |
| 2 Nov 2026 | 2,406.00 | 2,441.90 | 2,252.40 | 2,370.00 | -1.50% | 189.50 | 1.36 Cr |
| 26 Oct 2026 | 1,960.00 | 2,405.50 | 1,951.60 | 2,405.50 | +22.73% | 453.90 | 1.80 Cr |
| 19 Oct 2026 | 2,060.10 | 2,089.00 | 1,933.50 | 1,970.00 | -4.37% | 155.50 | 58.41 L |
| 12 Oct 2026 | 2,044.10 | 2,086.00 | 2,007.80 | 2,060.10 | +0.78% | 78.20 | 63.25 L |
| 5 Oct 2026 | 1,994.00 | 2,065.20 | 1,955.10 | 2,036.60 | +2.14% | 110.10 | 78.24 L |
| 28 Sept 2026 | 2,000.00 | 2,024.90 | 1,952.10 | 1,984.00 | -0.80% | 72.80 | 62.40 L |
| 21 Sept 2026 | 1,966.60 | 2,055.30 | 1,963.80 | 2,007.00 | +2.05% | 91.50 | 78.51 L |
| 14 Sept 2026 | 1,975.00 | 1,982.00 | 1,863.50 | 1,954.00 | -1.06% | 118.50 | 87.11 L |
Historical price and volume data · Showing 1–10 of 262
03/Valuation & returns
Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.
Price ÷ earnings per share
Worse than sector by 304%
Price ÷ book value per share
Worse than sector by 387%
Net income ÷ total assets
Better than sector by 873%
Net income ÷ shareholders' equity
Better than sector by 5627%
EBIT ÷ capital employed
Better than sector by 35%
Liquid assets ÷ current liabilities
Worse than sector by 86%
Enterprise value ÷ EBITDA
Worse than sector by 129%
04/Business
Sector: Pharmaceuticals
Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers an integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. It operates through four divisions: Generics API, Generics FDF, CDMO custom synthesis (Laurus Synthesis), and Biotechnology (Laurus Bio). The Generics API is a third-party API supplier for antiretrovirals. The Generic FDF business focuses on oral solid formulations. Laurus Synthesis provides drug development and manufacturing services to global pharma, crop science, animal health, and others. Laurus Bio offers comprehensive services from clone and strain engineering to production, supporting clients across the microbial precision fermentation spectrum. Its solutions cater for sectors, such as regenerative medicine, vaccines, cultured meat, and others.
reported in crore
reported in billion
Market capitalisation is reported at the sector-constituent level, not the standalone company level.
05/Profit & loss
Quarterly figures in ₹ crore. Growth marked reported is provided; margins are derived.
| Revenue | 2,219 | 2,035 | 1,823 | 1,784 |
|---|---|---|---|---|
| Revenue growthreported | 9.0% | 11.6% | 2.2% | — |
| Operating profit | 592 | 481 | 361 | 327 |
| Operating profit growthreported | 22.9% | 33.2% | 10.7% | — |
| Operating marginderived | 26.7% | 23.6% | 19.8% | 18.3% |
| Net profit | 437 | 362 | 282 | 253 |
| Net profit growthreported | 20.6% | 28.4% | 11.4% | — |
| Net marginderived | 19.7% | 17.8% | 15.5% | 14.2% |
| EPS — basic₹/share, annual | — | — | 16.47 | — |
Figures in ₹ crore. Margin rows are computed from the reported values.
| Revenue | 6,813 | 5,554 | 5,041 | 6,041 |
|---|---|---|---|---|
| Other Income | 55 | 75 | 26 | 6 |
| Total Revenue | 6,868 | 5,629 | 5,067 | 6,047 |
| Total Expenses | 5,686 | 5,145 | 4,831 | 4,938 |
| Profit Before Tax | 1,182 | 484 | 236 | 1,109 |
| Tax | 292 | 130 | 68 | 312 |
| Profit After Tax | 890 | 354 | 168 | 797 |
| EPS - Basic | 16.47 | 6.65 | 2.98 | 14.69 |
| EPS - Diluted | 16.45 | 6.64 | 2.97 | 14.64 |
This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.
06/Balance sheet
Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.
| Total assets | 10,511 | 9,336 | 8,387 | 7,660 |
|---|---|---|---|---|
| Total liabilities | 5,080 | 4,733 | 4,271 | 3,612 |
| Net worthderived | 5,431 | 4,603 | 4,116 | 4,049 |
| Liabilities ÷ assetsderived | 48.3% | 50.7% | 50.9% | 47.1% |
| Asset growthderived | 12.6% | 11.3% | 9.5% | — |
Figures in ₹ crore. Stacked chart height equals total assets.
| Non-Current Assets | 5,682 | 5,003 | 4,552 | 4,199 |
|---|---|---|---|---|
| Current Assets | 4,829 | 4,332 | 3,835 | 3,462 |
| Total Assets | 10,511 | 9,336 | 8,387 | 7,660 |
| Current Liabilities | 3,635 | 3,540 | 3,112 | 2,432 |
| Net Current Asset | 1,194 | 793 | 723 | 1,029 |
| Non-Current Liabilities | 1,444 | 1,193 | 1,159 | 1,179 |
| Equity Capital | 5,431 | 4,603 | 4,116 | 4,049 |
| Total Equity & Liabilities | 10,511 | 9,336 | 8,387 | 7,660 |
Figures in ₹ crore unless the line item is per-share.
07/Cash flow
Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.
| Operating activities | 1,624 | 602 | 666 | 994 |
|---|---|---|---|---|
| Operating changereported | 169.8% | -9.6% | -33.0% | — |
| Investing activities | -1,089 | -682 | -822 | -996 |
| Investing changereported | -59.7% | 17.1% | 17.4% | — |
| Financing activities | -525 | 39 | 250 | -27 |
| Financing changereported | -1435.8% | -84.3% | 1037.8% | — |
| Net cash flowderived | 10 | -41 | 93 | -29 |
| Free cash flowoperating + investing | 535 | -80 | -157 | -2 |
Figures in ₹ crore.
| Profit before tax | 1,182 | 484 | 236 | 1,109 |
|---|---|---|---|---|
| Income before WC changes | 1,892 | 1,114 | 799 | 1,595 |
| Change in Assets | -562 | -543 | -275 | -136 |
| Change in Liabilities | 587 | 168 | 246 | -179 |
| Change in WC | 25 | -375 | -29 | -315 |
| Cash flow from Operations | 1,624 | 602 | 666 | 994 |
| Cash flow from Investing | -1,089 | -682 | -822 | -996 |
| Cash flow from Financing | -525 | 39 | 250 | -27 |
| Total Cash Flow | 10 | -41 | 93 | -29 |
| Cash (Start of the year) | 100 | 139 | 46 | 75 |
| Cash (End of the year) | 113 | 100 | 139 | 46 |
Figures in ₹ crore unless the line item is per-share.
09/Events
Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.
| DividendInterim | ₹1.00 | 50.0% | 06 Nov 2026 | 06 Nov 2026 | 29 Oct 2026 | |
| DividendInterim | ₹1.20 | 60.0% | 08 May 2026 | 08 May 2026 | 30 Apr 2026 |
10/Comparison
Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.
| SUNPHARMASUN Pharmaceutical IND L | Pharmaceuticals | ₹1,884.90 | -0.79% | 19.16 L | ₹4,52,299 Cr | $50.26B | |
| DIVISLABDivi S Laboratories Ltd | Pharmaceuticals | ₹11,180.50 | +0.02% | 4.05 L | ₹2,97,325 Cr | $33.04B | |
| TORNTPHARMTorrent Pharmaceuticals L | Pharmaceuticals | ₹4,689.50 | +1.70% | 2.00 L | ₹1,78,727 Cr | $19.86B | |
| ZYDUSLIFEZydus Lifesciences Ltd | Pharmaceuticals | ₹1,200.00 | -0.24% | 7.80 L | ₹1,19,207 Cr | $13.25B | |
| DRREDDYDR. Reddy S Laboratories | Pharmaceuticals | ₹1,390.20 | -0.76% | 8.31 L | ₹1,16,145 Cr | $12.90B | |
| CIPLACipla Ltd | Pharmaceuticals | ₹1,415.00 | -0.25% | 14.84 L | ₹1,14,312 Cr | $12.70B | |
| MANKINDMankind Pharma Limited | Pharmaceuticals | ₹2,665.00 | +1.37% | 4.56 L | ₹1,09,870 Cr | $12.21B | |
| AUROPHARMAAurobindo Pharma Ltd | Pharmaceuticals | ₹1,799.00 | -0.37% | 8.11 L | ₹1,03,298 Cr | $11.48B | |
| LUPINLupin Limited | Pharmaceuticals | ₹2,014.00 | +0.76% | 6.31 L | ₹91,916 Cr | $10.21B | |
| GLENMARKGlenmark Pharmaceuticals | Pharmaceuticals | ₹2,648.00 | +1.51% | 5.40 L | ₹74,733 Cr | $8.30B |
Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10
11/Coverage
Articles published in the last seven days, paginated by the provider.

Cupid, Ather Energy, and Laurus Labs are among the top six stocks which have quietly rallied up to the tune of 200% in the last six months despite market volatility. Here's what investors need to know.
Showing 1–1 of 1 article